<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02868905</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A01686-43</org_study_id>
    <nct_id>NCT02868905</nct_id>
  </id_info>
  <brief_title>Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women</brief_title>
  <acronym>Oba</acronym>
  <official_title>Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women - Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare average methylation of epigenetic markers on genomic
      DNA and some genes (APP, BACE, LRP, SorL1) involved in cerebral amyloid homeostasis:

        -  Of obese young adults and healthy young adults

        -  Of obese young adults and individuals affected by Alzheimer's disease (AD) having been
           obese at young adult age (&lt;50 years old) or individuals affected by Alzheimer's disease
           (AD) having never been obese.

      The secondary purpose is to determine if there is an association between the frequency of
      these epigenetic markers and elements associated to the metabolic syndrome (lipidic and
      glycemic analysis, leptinemia, inflammation markers) and clinical ones (visceral fat mass,
      body mass index) in young adults.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methylation of CpG islands in genomic DNA and in 4 target genes involved in AD (APP, SorLA/LR11, BACE1, LRP) in obese and AD subjects</measure>
    <time_frame>day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>body mass index</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visceral fat mass level</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>leptinemia by ELISA</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulinemia by ELISA</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemia</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triglyceridemia</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol level in blood</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive C protein level in blood</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Obesity</condition>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Obese group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-obese AD group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-obese AD groups</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese AD group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Obese AD group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Obese group</arm_group_label>
    <arm_group_label>Non-obese AD group</arm_group_label>
    <arm_group_label>Obese AD group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group 1:

          -  18-50 year old women, age- (10 years) and sociocultural-matched with group 2

          -  Non obese and never been obese

          -  18.5 &lt; BMI &lt; 25

          -  Folstein MMS &gt; 27

          -  Informed consent

          -  Affiliation to social security plan

        Group 2:

          -  18-50 year old women, age- (10 years) and sociocultural-matched with group 1

          -  Waist size &gt; 88cm

          -  30 &lt; BMI &lt; 45

          -  Insulin-resistant patients (Insulin resistance index, HOMA-IR &gt; 3.8)

          -  Obesity onset during childhood (pre-puberty period)

          -  Folstein MMS &gt; 27

          -  Informed consent

          -  Affiliation to social security plan

        Group 3:

          -  &gt;60 year old women, age- (10 years) matched with group 4

          -  No obesity history (18.5 ≤ BMI &lt; 25 at adult age)

          -  Sporadic forms of mild to moderate AD with demonstration of AD physiopathologic
             process according to new recommendations of 2011 of National Institute on Aging and
             Alzheimer's Association on diagnostic guidelines for Alzheimer's disease

          -  15&lt; Folstein MMS ≤ 26

          -  Informed consent

          -  Affiliation to social security plan

        Group 4:

          -  &gt;60 year old women, age- (10 years) matched with group 3

          -  Obesity history (BMI &gt; 30 at least one time at adult age)

          -  Sporadic forms of mild to moderate AD with demonstration of AD physiopathologic
             process according to new recommendations of 2011 of National Institute on Aging and
             Alzheimer's Association on diagnostic guidelines for Alzheimer's disease

          -  15 &lt; Folstein MMS ≤ 26

          -  Informed consent

          -  Affiliation to social security plan

        Exclusion Criteria:

        Group 1:

          -  &lt;18

          -  Patient under guardianship, curatorship or judicial protection

          -  Folate supplementation

          -  Diabetic or glucose intolerant subjects

          -  Present participation to another study with neuropsychological evaluation and/or drug
             administration

          -  Pregnant women

        Groups 2,3 and 4:

          -  &lt;18

          -  Patient under guardianship, curatorship or judicial protection

          -  Folate supplementation

          -  Present participation to another study with neuropsychological evaluation and/or drug
             administration

        Group 2:

        - Pregnant women

        Group 4:

        - Obese or overweight patients (BMI&gt;25)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thérèse RIVASSEAU-JONVEAUX</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Gériatrie, Hôpitaux de Brabois, 3 rue du Morvan, 54 511 Vandoeuvre-lès-Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thérèse RIVASSEAU-JONVEAUX, Dr</last_name>
    <email>t.jonveaux@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

